Novo Nordisk’s CagriSema beaten by Lilly’s Zepbound in head-to-head obesity trial
Elizabeth Cairns / endpoints - Novo Nordisk’s GLP-1/amylin combo drug CagriSema was not as good as Eli Lilly’s marketed obesity shot Zepbound in a head-to-head study, the Danish company said Monday. Patients in the REDEFINE 4 ...
AI Summary: In a direct comparator study, Eli Lilly’s marketed obesity drug Zepbound produced greater mean weight loss than Novo Nordisk’s experimental CagriSema. The result complicates the competitive landscape for anti‑obesity medicines and will influence prescribers, payers and the almighty market share tussle.
Warning: Undefined variable $thumbnail in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 61
Related Stories
Warning: Undefined variable $top_stories in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 128
GLP‑1 drugs associated with lower addiction risk in large study / 2 months
Novo Nordisk oral GLP‑1 pill clears FDA for obesity treatment / 5 months
Novo Nordisk commits $2.1B to Vivtex to pursue oral obesity medicines / 2 months
Novo Nordisk legal action threat over copycat Wegovy pill / 3 months
Novo Nordisk GLP‑1 Trials Fail to Check Alzheimer’s Progression / 6 months
Lilly fights classification ruling as stockpile and compounding lawsuits swirl / 3 months
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Pfizer, Public Health, Novo Nordisk, Supply Chain and look for the RSS link.
StackHealth Time Machine